Whilst small-rely MBL rarely progresses to CLL, high-count MBL progresses to CLL demanding therapy in a charge of one% to 2% per annum. Substantial-count MBL is distinguished from Rai 0 CLL dependant on whether the B-mobile rely is higher than or below five × 109/L. Whilst people with each higher-rely MBL and CLL Rai phase 0 are at improved chance